Kelley Discusses Efficacy and Safety Considerations With the STRIDE Regimen in HCC

2 Просмотры· 08/31/23
OncLive® On Air
OncLive® On Air
0 Подписчики
0
В

Dr Kelley discusses standard first-line treatment options for patients with advanced HCC, key findings from the phase 3 HIMALAYA trial, and the safety profile of the STRIDE regimen in this population.

Показать больше

 0 Комментарии sort   Сортировать по


Следующий